Menu Search
Equities

Sawai Group Holdings Co Ltd

4887:TYO

Sawai Group Holdings Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,972.00
  • Today's Change-2.50 / -0.13%
  • Shares traded714.00k
  • 1 Year change+18.04%
  • Beta0.6764
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy2
Outperform3
Hold2
Sell1
Strong Sell1

Share price forecast in JPY

The 9 analysts offering 12 month price targets for Sawai Group Holdings Co Ltd have a median target of 2,400.00, with a high estimate of 3,000.00 and a low estimate of 1,700.00. The median estimate represents a 21.70% increase from the last price of 1,972.00.
High52.1%3,000.00
Med21.7%2,400.00
Low-13.8%1,700.00

Dividends in JPY

In 2024, Sawai Group Holdings Co Ltd reported a dividend of 43.33 JPY, equaling last years dividend. The 8 analysts covering the company expect dividends of 53.00 JPY for the upcoming fiscal year, an increase of 22.31%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in JPY

On Nov 11, 2024, Sawai Group Holdings Co Ltd reported 2nd quarter 2025 earnings of 28.40 per share.
The next earnings announcement is expected on Feb 11, 2025.
Average growth rate+1,928.70%
Sawai Group Holdings Co Ltd reported annual 2024 earnings of 104.22 per share on May 13, 2024.
Average growth rate-13.96%
More ▼

Revenue history & estimates in JPY

Sawai Pharmaceutical Co., Ltd. had 2nd quarter 2025 revenues of 43.54m. This missed the 49.22m consensus estimate of the 5 analysts following the company. This was 17.83% below the prior year's 2nd quarter results.
Average growth rate+0.17%
Sawai Pharmaceutical Co., Ltd. had revenues for the full year 2024 of 176.86m. This was 11.72% below the prior year's results.
Average growth rate-0.57%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.